Global Gene Therapy Market - 2025-2033
Gene Therapy Market Size
The global gene therapy market size reached US$ 4.80 Billion in 2024 and is expected to reach US$ 35.91 Billion by 2033, growing at a CAGR of 23.1% during the forecast period 2025-2033.
Gene Therapy Market Overview
The gene therapy market is experiencing rapid growth, driven by advancements in genomics, biotechnology and personalized medicine. Gene therapy is revolutionizing genetic disorders, rare diseases and cancer treatments. The market has witnessed significant expansion due to the increasing R&D investments, strategic partnerships among key players and approval of novel gene therapies in emerging markets.
For instance, in January 2024, Vertex Pharmaceuticals Incorporated released the Saudi Food and Drug Authority (SFDA) granted Marketing Authorization for CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). CASGEVY is approved for treating people 12 years of age and older with SCD or TDT.
Additionally, gene therapy transforming oncology by developing products for various types of cancers. For instance, in January 2023, Ferring Pharmaceuticals cleared that ADSTILADRIN (nadofaragene firadenovec-vncg) is fully available across the U.S. for healthcare providers to prescribe for their adult patients with high-risk Bacillus Calmette-Gu?rin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Approved by the U.S. Food & Drug Administration (FDA), ADSTILADRIN is the first and only FDA-approved intravesical gene therapy for adults with NMIBC who no longer respond to standard therapy.
Gene Therapy Market Dynamics: Drivers & Restraints
Expansion into the rare diseases is significantly driving the gene therapy market growth
Rare diseases, which are genetic in nature, often have limited or no effective treatment options, making them ideal targets for gene therapies. The unique nature of these diseases presents a substantial opportunity for gene therapy to provide curative treatments where traditional approaches fail. For instance, Luxturna, a gene therapy treating children and adult patients with an inherited form of vision loss that may result in blindness. Luxturna is the first directly administered gene therapy approved in the U.S. that targets a disease caused by mutations in a specific gene.
Spinal Muscular Atrophy (SMA) is a rare genetic disorder that leads to progressive muscle weakness. Zolgensma, a gene therapy, offers a one-time treatment that has demonstrated significant improvements in survival and motor function for children with SMA. Hemophilia, another rare genetic disorder, requires lifelong treatment with clotting factor concentrates.
For instance, in February 2025, CSL Behring announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of HEMGENIX (etranacogene dezaparvovec-drlb) gene therapy for adults living with hemophilia B. As more gene therapies for rare diseases gain approval, the market will see a diversification of therapies, addressing a wider range of conditions.
High cost associated with the gene therapies are hampering the market growth
The high cost of gene therapies is one of the most significant challenges impacting the growth and accessibility of the gene therapy market. While gene therapies have shown curative potential for many serious diseases, their expensive price tags pose barriers to widespread adoption. For instance, the gene therapies Zynteglo and Skysona are priced at US$ 2.8 million and US$ 3 million per dose. Moreover, Zolgensma has a reported list price of US$ 2.1 million.
The development of gene therapies is an expensive, lengthy process. Clinical trials for gene therapies often span several years and involve high patient monitoring and expensive regulatory approval procedures. For instance, Luxturna, a gene therapy for Leber’s congenital amaurosis, took over 10 years from development to approval, and its cost is $850,000 per patient.
Many gene therapies are personalized treatments that are tailored to the genetic makeup of individual patients, requiring bespoke production for each case. This individualization further increases costs. For instance, CAR-T therapies such as Yescarta and Kymriah are customized for each patient by collecting and modifying the patient’s own T-cells, a process that involves complex manufacturing and quality control measures. These therapies can cost over $300,000 to $400,000 per patient.
Gene Therapy Market, Segment Analysis
The global gene therapy market is segmented based on approach, vector type, technique, application, and region.
Vector Type:
The viral vectors segment is expected to hold 65.13% of the market share in 2024 in the gene therapy market
Viral vectors are modified viruses used as delivery vehicles to introduce genetic material into cells for gene therapy. They exploit viruses' natural ability to transport their genomes into host cells, a process called transduction. The choice of viral vector depends on factors such as efficiency, safety, toxicity, stability, and the desired duration of transgene expression.
Currently, there are four types of viral vectors used in gene therapy: adenovirus, adeno-associated virus (AAV), lentivirus, and gamma-retrovirus (?-retroviral). Each vector type requires a complex manufacturing process. These vectors are chosen for their ability to efficiently deliver genetic material, each having its strengths and weaknesses depending on the specific therapeutic application.
Furthermore, key players’ strategies such as partnerships, collaborations, and technological advancements would propel this segment’s growth. For instance, in October 2024, Roche is partnering with Dyno Therapeutics to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases, potentially worth over $1 billion to Dyno. This collaboration, the second between the companies, grants Roche further access to Dyno's platform and sequence design technologies for in-vivo gene delivery.
Also, in March 2024, Charles River Laboratories International, Inc. introduced Modular and Fast Track frameworks to streamline viral vector technology transfer to its Maryland-based Center of Excellence (CoE). This program, leveraging decades of viral vector contract development and manufacturing organization (CDMO) experience, aims to expedite process transfer in as little as nine months. These frameworks provide stability, prevent program delays, and offer a cohesive "concept-to-cure" solution for gene therapy developers. Hence, the above-mentioned factors help the viral vectors segment to grow during the forecast period.
Gene Therapy Market, Geographical Analysis
North America is expected to dominate the global gene therapy market with 62.60% share in 2024
The gene therapy market in the North America region is expected to be driven by various factors like the increasing prevalence of cancer, genetic disorders, and other rare diseases. As per clinical Case Reports research publication in February 2024, SMA, a genetic disorder resulting from mutations in both copies of the SMN1 gene in cells, affects 1 in 6,000 to 1 in 10,000 children. According to the National Heart, Lung, and Blood data in September 2024, Sickle cell disease (SCD) affects approximately 100,000 people in the United States, with over 90% being non-Hispanic Black or African American, and 8 million people worldwide. The demand for gene-based treatments is expected to accelerate, driving the overall growth of the gene therapy market.
Furthermore, in this region, a major number of key players’ presence, a well-advanced healthcare infrastructure, technological advances, product launches, approvals, and increasing research activities are driving the gene therapy market in the North American region.
For instance, in September 2024, Vertex Pharmaceuticals Incorporated announced that Health Canada granted marketing authorization for CASGEVY (exagamglogene autotemcel) for individuals 12 years and older with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta-thalassemia (TDT). CASGEVY is an autologous genome-edited hematopoietic stem cell-based therapy. It is estimated that approximately 2,000 patients in Canada are eligible for this treatment, with the majority having SCD.
Similarly, in March 2024, Orchard Therapeutics, acquired by Kyowa Kirin, announced its U.S. launch plans for Lenmeldy (atidarsagene autotemcel), the first FDA-approved gene therapy for children with early-onset metachromatic leukodystrophy (MLD). MLD is a rare, rapidly progressive, and ultimately fatal neurometabolic disease affecting roughly one in 100,000 live births.
Gene Therapy Market Competitive Landscape
Top companies in the gene therapy market include Alnylam Pharmaceuticals, Inc., Spark Therapeutics, Inc., Novartis AG, bluebird bio, Inc., Ferring Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics, Inc., CSL Behring LLC, Amgen, Inc., Orchard Therapeutics group., Krystal Biotech, Inc., and among others.
The global gene therapy market report delivers a detailed analysis with 73 key tables, more than 64 visually impactful figures, and 168 pages of expert insights, providing a complete view of the market landscape.
The global gene therapy market size reached US$ 4.80 Billion in 2024 and is expected to reach US$ 35.91 Billion by 2033, growing at a CAGR of 23.1% during the forecast period 2025-2033.
Gene Therapy Market Overview
The gene therapy market is experiencing rapid growth, driven by advancements in genomics, biotechnology and personalized medicine. Gene therapy is revolutionizing genetic disorders, rare diseases and cancer treatments. The market has witnessed significant expansion due to the increasing R&D investments, strategic partnerships among key players and approval of novel gene therapies in emerging markets.
For instance, in January 2024, Vertex Pharmaceuticals Incorporated released the Saudi Food and Drug Authority (SFDA) granted Marketing Authorization for CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). CASGEVY is approved for treating people 12 years of age and older with SCD or TDT.
Additionally, gene therapy transforming oncology by developing products for various types of cancers. For instance, in January 2023, Ferring Pharmaceuticals cleared that ADSTILADRIN (nadofaragene firadenovec-vncg) is fully available across the U.S. for healthcare providers to prescribe for their adult patients with high-risk Bacillus Calmette-Gu?rin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Approved by the U.S. Food & Drug Administration (FDA), ADSTILADRIN is the first and only FDA-approved intravesical gene therapy for adults with NMIBC who no longer respond to standard therapy.
Gene Therapy Market Dynamics: Drivers & Restraints
Expansion into the rare diseases is significantly driving the gene therapy market growth
Rare diseases, which are genetic in nature, often have limited or no effective treatment options, making them ideal targets for gene therapies. The unique nature of these diseases presents a substantial opportunity for gene therapy to provide curative treatments where traditional approaches fail. For instance, Luxturna, a gene therapy treating children and adult patients with an inherited form of vision loss that may result in blindness. Luxturna is the first directly administered gene therapy approved in the U.S. that targets a disease caused by mutations in a specific gene.
Spinal Muscular Atrophy (SMA) is a rare genetic disorder that leads to progressive muscle weakness. Zolgensma, a gene therapy, offers a one-time treatment that has demonstrated significant improvements in survival and motor function for children with SMA. Hemophilia, another rare genetic disorder, requires lifelong treatment with clotting factor concentrates.
For instance, in February 2025, CSL Behring announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of HEMGENIX (etranacogene dezaparvovec-drlb) gene therapy for adults living with hemophilia B. As more gene therapies for rare diseases gain approval, the market will see a diversification of therapies, addressing a wider range of conditions.
High cost associated with the gene therapies are hampering the market growth
The high cost of gene therapies is one of the most significant challenges impacting the growth and accessibility of the gene therapy market. While gene therapies have shown curative potential for many serious diseases, their expensive price tags pose barriers to widespread adoption. For instance, the gene therapies Zynteglo and Skysona are priced at US$ 2.8 million and US$ 3 million per dose. Moreover, Zolgensma has a reported list price of US$ 2.1 million.
The development of gene therapies is an expensive, lengthy process. Clinical trials for gene therapies often span several years and involve high patient monitoring and expensive regulatory approval procedures. For instance, Luxturna, a gene therapy for Leber’s congenital amaurosis, took over 10 years from development to approval, and its cost is $850,000 per patient.
Many gene therapies are personalized treatments that are tailored to the genetic makeup of individual patients, requiring bespoke production for each case. This individualization further increases costs. For instance, CAR-T therapies such as Yescarta and Kymriah are customized for each patient by collecting and modifying the patient’s own T-cells, a process that involves complex manufacturing and quality control measures. These therapies can cost over $300,000 to $400,000 per patient.
Gene Therapy Market, Segment Analysis
The global gene therapy market is segmented based on approach, vector type, technique, application, and region.
Vector Type:
The viral vectors segment is expected to hold 65.13% of the market share in 2024 in the gene therapy market
Viral vectors are modified viruses used as delivery vehicles to introduce genetic material into cells for gene therapy. They exploit viruses' natural ability to transport their genomes into host cells, a process called transduction. The choice of viral vector depends on factors such as efficiency, safety, toxicity, stability, and the desired duration of transgene expression.
Currently, there are four types of viral vectors used in gene therapy: adenovirus, adeno-associated virus (AAV), lentivirus, and gamma-retrovirus (?-retroviral). Each vector type requires a complex manufacturing process. These vectors are chosen for their ability to efficiently deliver genetic material, each having its strengths and weaknesses depending on the specific therapeutic application.
Furthermore, key players’ strategies such as partnerships, collaborations, and technological advancements would propel this segment’s growth. For instance, in October 2024, Roche is partnering with Dyno Therapeutics to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases, potentially worth over $1 billion to Dyno. This collaboration, the second between the companies, grants Roche further access to Dyno's platform and sequence design technologies for in-vivo gene delivery.
Also, in March 2024, Charles River Laboratories International, Inc. introduced Modular and Fast Track frameworks to streamline viral vector technology transfer to its Maryland-based Center of Excellence (CoE). This program, leveraging decades of viral vector contract development and manufacturing organization (CDMO) experience, aims to expedite process transfer in as little as nine months. These frameworks provide stability, prevent program delays, and offer a cohesive "concept-to-cure" solution for gene therapy developers. Hence, the above-mentioned factors help the viral vectors segment to grow during the forecast period.
Gene Therapy Market, Geographical Analysis
North America is expected to dominate the global gene therapy market with 62.60% share in 2024
The gene therapy market in the North America region is expected to be driven by various factors like the increasing prevalence of cancer, genetic disorders, and other rare diseases. As per clinical Case Reports research publication in February 2024, SMA, a genetic disorder resulting from mutations in both copies of the SMN1 gene in cells, affects 1 in 6,000 to 1 in 10,000 children. According to the National Heart, Lung, and Blood data in September 2024, Sickle cell disease (SCD) affects approximately 100,000 people in the United States, with over 90% being non-Hispanic Black or African American, and 8 million people worldwide. The demand for gene-based treatments is expected to accelerate, driving the overall growth of the gene therapy market.
Furthermore, in this region, a major number of key players’ presence, a well-advanced healthcare infrastructure, technological advances, product launches, approvals, and increasing research activities are driving the gene therapy market in the North American region.
For instance, in September 2024, Vertex Pharmaceuticals Incorporated announced that Health Canada granted marketing authorization for CASGEVY (exagamglogene autotemcel) for individuals 12 years and older with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta-thalassemia (TDT). CASGEVY is an autologous genome-edited hematopoietic stem cell-based therapy. It is estimated that approximately 2,000 patients in Canada are eligible for this treatment, with the majority having SCD.
Similarly, in March 2024, Orchard Therapeutics, acquired by Kyowa Kirin, announced its U.S. launch plans for Lenmeldy (atidarsagene autotemcel), the first FDA-approved gene therapy for children with early-onset metachromatic leukodystrophy (MLD). MLD is a rare, rapidly progressive, and ultimately fatal neurometabolic disease affecting roughly one in 100,000 live births.
Gene Therapy Market Competitive Landscape
Top companies in the gene therapy market include Alnylam Pharmaceuticals, Inc., Spark Therapeutics, Inc., Novartis AG, bluebird bio, Inc., Ferring Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics, Inc., CSL Behring LLC, Amgen, Inc., Orchard Therapeutics group., Krystal Biotech, Inc., and among others.
The global gene therapy market report delivers a detailed analysis with 73 key tables, more than 64 visually impactful figures, and 168 pages of expert insights, providing a complete view of the market landscape.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Approach
2.4. Snippet by Vector Type
2.5. Snippet by Technique
2.6. Snippet by Application
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Expansion into the Rare Diseases
3.1.1.2. Growing Utilization of Advanced Delivery Vectors
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. High Cost associated with the Gene Therapies
3.1.2.2. Safety and Long-Term Efficacy Concerns
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Expansion into Complex & Chronic Diseases
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GENE THERAPY MARKET, BY APPROACH
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
5.1.2. Market Attractiveness Index, By Approach
5.2. In-Vivo*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Ex-vivo
6. GENE THERAPY MARKET, BY VECTOR TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vector Type
6.1.2. Market Attractiveness Index, By Vector Type
6.2. Viral Vectors*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Adeno-Associated Virus
6.2.4. Herpes Simplex Virus
6.2.5. Lentivirus
6.3. Non-Viral Vectors
7. GENE THERAPY MARKET, BY TECHNIQUE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
7.1.2. Market Attractiveness Index, By Technique
7.2. Gene Addition*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Gene Silencing
7.4. Gene Editing
8. GENE THERAPY MARKET, BY APPLICATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Rare Diseases*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Musculoskeletal Conditions
8.4. Blood Disorders
8.5. Oncology
8.6. Ophthalmology
8.7. Others
9. GENE THERAPY MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vector Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vector Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. UK
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vector Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. China
9.4.7.2. India
9.4.7.3. Japan
9.4.7.4. South Korea
9.4.7.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vector Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. Brazil
9.5.7.2. Argentina
9.5.7.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vector Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Spark Therapeutics, Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.5. SWOT Analysis
11.2. Novartis AG
11.3. bluebird bio, Inc.
11.4. Ferring Pharmaceuticals Inc.
11.5. Vertex Pharmaceuticals Incorporated
11.6. Sarepta Therapeutics, Inc.
11.7. CSL Behring LLC
11.8. Alnylam Pharmaceuticals, Inc.
11.9. Amgen, Inc.
11.10. Orchard Therapeutics group.
11.11. Krystal Biotech, Inc.
LIST NOT EXHAUSTIVE
12. ASSUMPTION AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Approach
2.4. Snippet by Vector Type
2.5. Snippet by Technique
2.6. Snippet by Application
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Expansion into the Rare Diseases
3.1.1.2. Growing Utilization of Advanced Delivery Vectors
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. High Cost associated with the Gene Therapies
3.1.2.2. Safety and Long-Term Efficacy Concerns
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Expansion into Complex & Chronic Diseases
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GENE THERAPY MARKET, BY APPROACH
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
5.1.2. Market Attractiveness Index, By Approach
5.2. In-Vivo*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Ex-vivo
6. GENE THERAPY MARKET, BY VECTOR TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vector Type
6.1.2. Market Attractiveness Index, By Vector Type
6.2. Viral Vectors*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Adeno-Associated Virus
6.2.4. Herpes Simplex Virus
6.2.5. Lentivirus
6.3. Non-Viral Vectors
7. GENE THERAPY MARKET, BY TECHNIQUE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
7.1.2. Market Attractiveness Index, By Technique
7.2. Gene Addition*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Gene Silencing
7.4. Gene Editing
8. GENE THERAPY MARKET, BY APPLICATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Rare Diseases*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Musculoskeletal Conditions
8.4. Blood Disorders
8.5. Oncology
8.6. Ophthalmology
8.7. Others
9. GENE THERAPY MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vector Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vector Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. UK
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vector Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. China
9.4.7.2. India
9.4.7.3. Japan
9.4.7.4. South Korea
9.4.7.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vector Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. Brazil
9.5.7.2. Argentina
9.5.7.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vector Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Spark Therapeutics, Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.5. SWOT Analysis
11.2. Novartis AG
11.3. bluebird bio, Inc.
11.4. Ferring Pharmaceuticals Inc.
11.5. Vertex Pharmaceuticals Incorporated
11.6. Sarepta Therapeutics, Inc.
11.7. CSL Behring LLC
11.8. Alnylam Pharmaceuticals, Inc.
11.9. Amgen, Inc.
11.10. Orchard Therapeutics group.
11.11. Krystal Biotech, Inc.
LIST NOT EXHAUSTIVE
12. ASSUMPTION AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
LIST OF TABLES
Table 1 Global Gene Therapy Market Value, By Approach, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Gene Therapy Market Value, By Vector Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Gene Therapy Market Value, By Technique, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Gene Therapy Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Gene Therapy Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Gene Therapy Market Value, By Approach, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Gene Therapy Market Value, By Approach, 2022-2033 (US$ Billion)
Table 8 Global Gene Therapy Market Value, By Vector Type, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Gene Therapy Market Value, By Vector Type, 2022-2033 (US$ Billion)
Table 10 Global Gene Therapy Market Value, By Technique, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Gene Therapy Market Value, By Technique, 2022-2033 (US$ Billion)
Table 12 Global Gene Therapy Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Gene Therapy Market Value, By Application, 2022-2033 (US$ Billion)
Table 14 Global Gene Therapy Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Gene Therapy Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Gene Therapy Market Value, By Approach, 2022-2033 (US$ Billion)
Table 17 North America Gene Therapy Market Value, By Vector Type, 2022-2033 (US$ Billion)
Table 18 North America Gene Therapy Market Value, By Technique, 2022-2033 (US$ Billion)
Table 19 North America Gene Therapy Market Value, By Application, 2022-2033 (US$ Billion)
Table 20 North America Gene Therapy Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 South America Gene Therapy Market Value, By Approach, 2022-2033 (US$ Billion)
Table 22 South America Gene Therapy Market Value, By Vector Type, 2022-2033 (US$ Billion)
Table 23 South America Gene Therapy Market Value, By Technique, 2022-2033 (US$ Billion)
Table 24 South America Gene Therapy Market Value, By Application, 2022-2033 (US$ Billion)
Table 25 South America Gene Therapy Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Europe Gene Therapy Market Value, By Approach, 2022-2033 (US$ Billion)
Table 27 Europe Gene Therapy Market Value, By Vector Type, 2022-2033 (US$ Billion)
Table 28 Europe Gene Therapy Market Value, By Technique, 2022-2033 (US$ Billion)
Table 29 Europe Gene Therapy Market Value, By Application, 2022-2033 (US$ Billion)
Table 30 Europe Gene Therapy Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 Asia-Pacific Gene Therapy Market Value, By Approach, 2022-2033 (US$ Billion)
Table 32 Asia-Pacific Gene Therapy Market Value, By Vector Type, 2022-2033 (US$ Billion)
Table 33 Asia-Pacific Gene Therapy Market Value, By Technique, 2022-2033 (US$ Billion)
Table 34 Asia-Pacific Gene Therapy Market Value, By Application, 2022-2033 (US$ Billion)
Table 35 Asia-Pacific Gene Therapy Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Gene Therapy Market Value, By Approach, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Gene Therapy Market Value, By Vector Type, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Gene Therapy Market Value, By Technique, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Gene Therapy Market Value, By Application, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Gene Therapy Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Spark Therapeutics, Inc.: Overview
Table 42 Spark Therapeutics, Inc.: Product Portfolio
Table 43 Spark Therapeutics, Inc.: Key Developments
Table 44 Novartis AG: Overview
Table 45 Novartis AG: Product Portfolio
Table 46 Novartis AG: Key Developments
Table 47 bluebird bio, Inc.: Overview
Table 48 bluebird bio, Inc.: Product Portfolio
Table 49 bluebird bio, Inc.: Key Developments
Table 50 Ferring Pharmaceuticals Inc.: Overview
Table 51 Ferring Pharmaceuticals Inc.: Product Portfolio
Table 52 Ferring Pharmaceuticals Inc.: Key Developments
Table 53 Vertex Pharmaceuticals Incorporated: Overview
Table 54 Vertex Pharmaceuticals Incorporated: Product Portfolio
Table 55 Vertex Pharmaceuticals Incorporated: Key Developments
Table 56 Sarepta Therapeutics, Inc.: Overview
Table 57 Sarepta Therapeutics, Inc.: Product Portfolio
Table 58 Sarepta Therapeutics, Inc.: Key Developments
Table 59 CSL Behring LLC: Overview
Table 60 CSL Behring LLC: Product Portfolio
Table 61 CSL Behring LLC: Key Developments
Table 62 Alnylam Pharmaceuticals, Inc.: Overview
Table 63 Alnylam Pharmaceuticals, Inc.: Product Portfolio
Table 64 Alnylam Pharmaceuticals, Inc.: Key Developments
Table 65 Amgen, Inc.: Overview
Table 66 Amgen, Inc.: Product Portfolio
Table 67 Amgen, Inc.: Key Developments
Table 68 Orchard Therapeutics group.: Overview
Table 69 Orchard Therapeutics group.: Product Portfolio
Table 70 Orchard Therapeutics group.: Key Developments
Table 71 Krystal Biotech, Inc.: Overview
Table 72 Krystal Biotech, Inc.: Product Portfolio
Table 73 Krystal Biotech, Inc.: Key Developments
Table 1 Global Gene Therapy Market Value, By Approach, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Gene Therapy Market Value, By Vector Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Gene Therapy Market Value, By Technique, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Gene Therapy Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Gene Therapy Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Gene Therapy Market Value, By Approach, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Gene Therapy Market Value, By Approach, 2022-2033 (US$ Billion)
Table 8 Global Gene Therapy Market Value, By Vector Type, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Gene Therapy Market Value, By Vector Type, 2022-2033 (US$ Billion)
Table 10 Global Gene Therapy Market Value, By Technique, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Gene Therapy Market Value, By Technique, 2022-2033 (US$ Billion)
Table 12 Global Gene Therapy Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Gene Therapy Market Value, By Application, 2022-2033 (US$ Billion)
Table 14 Global Gene Therapy Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Gene Therapy Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Gene Therapy Market Value, By Approach, 2022-2033 (US$ Billion)
Table 17 North America Gene Therapy Market Value, By Vector Type, 2022-2033 (US$ Billion)
Table 18 North America Gene Therapy Market Value, By Technique, 2022-2033 (US$ Billion)
Table 19 North America Gene Therapy Market Value, By Application, 2022-2033 (US$ Billion)
Table 20 North America Gene Therapy Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 South America Gene Therapy Market Value, By Approach, 2022-2033 (US$ Billion)
Table 22 South America Gene Therapy Market Value, By Vector Type, 2022-2033 (US$ Billion)
Table 23 South America Gene Therapy Market Value, By Technique, 2022-2033 (US$ Billion)
Table 24 South America Gene Therapy Market Value, By Application, 2022-2033 (US$ Billion)
Table 25 South America Gene Therapy Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Europe Gene Therapy Market Value, By Approach, 2022-2033 (US$ Billion)
Table 27 Europe Gene Therapy Market Value, By Vector Type, 2022-2033 (US$ Billion)
Table 28 Europe Gene Therapy Market Value, By Technique, 2022-2033 (US$ Billion)
Table 29 Europe Gene Therapy Market Value, By Application, 2022-2033 (US$ Billion)
Table 30 Europe Gene Therapy Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 Asia-Pacific Gene Therapy Market Value, By Approach, 2022-2033 (US$ Billion)
Table 32 Asia-Pacific Gene Therapy Market Value, By Vector Type, 2022-2033 (US$ Billion)
Table 33 Asia-Pacific Gene Therapy Market Value, By Technique, 2022-2033 (US$ Billion)
Table 34 Asia-Pacific Gene Therapy Market Value, By Application, 2022-2033 (US$ Billion)
Table 35 Asia-Pacific Gene Therapy Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Gene Therapy Market Value, By Approach, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Gene Therapy Market Value, By Vector Type, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Gene Therapy Market Value, By Technique, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Gene Therapy Market Value, By Application, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Gene Therapy Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Spark Therapeutics, Inc.: Overview
Table 42 Spark Therapeutics, Inc.: Product Portfolio
Table 43 Spark Therapeutics, Inc.: Key Developments
Table 44 Novartis AG: Overview
Table 45 Novartis AG: Product Portfolio
Table 46 Novartis AG: Key Developments
Table 47 bluebird bio, Inc.: Overview
Table 48 bluebird bio, Inc.: Product Portfolio
Table 49 bluebird bio, Inc.: Key Developments
Table 50 Ferring Pharmaceuticals Inc.: Overview
Table 51 Ferring Pharmaceuticals Inc.: Product Portfolio
Table 52 Ferring Pharmaceuticals Inc.: Key Developments
Table 53 Vertex Pharmaceuticals Incorporated: Overview
Table 54 Vertex Pharmaceuticals Incorporated: Product Portfolio
Table 55 Vertex Pharmaceuticals Incorporated: Key Developments
Table 56 Sarepta Therapeutics, Inc.: Overview
Table 57 Sarepta Therapeutics, Inc.: Product Portfolio
Table 58 Sarepta Therapeutics, Inc.: Key Developments
Table 59 CSL Behring LLC: Overview
Table 60 CSL Behring LLC: Product Portfolio
Table 61 CSL Behring LLC: Key Developments
Table 62 Alnylam Pharmaceuticals, Inc.: Overview
Table 63 Alnylam Pharmaceuticals, Inc.: Product Portfolio
Table 64 Alnylam Pharmaceuticals, Inc.: Key Developments
Table 65 Amgen, Inc.: Overview
Table 66 Amgen, Inc.: Product Portfolio
Table 67 Amgen, Inc.: Key Developments
Table 68 Orchard Therapeutics group.: Overview
Table 69 Orchard Therapeutics group.: Product Portfolio
Table 70 Orchard Therapeutics group.: Key Developments
Table 71 Krystal Biotech, Inc.: Overview
Table 72 Krystal Biotech, Inc.: Product Portfolio
Table 73 Krystal Biotech, Inc.: Key Developments
LIST OF FIGURES
Figure 1 Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Gene Therapy Market Share, By Approach, 2024 & 2033 (%)
Figure 3 Global Gene Therapy Market Share, By Vector Type, 2024 & 2033 (%)
Figure 4 Global Gene Therapy Market Share, By Technique, 2024 & 2033 (%)
Figure 5 Global Gene Therapy Market Share, By Application, 2024 & 2033 (%)
Figure 6 Global Gene Therapy Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Gene Therapy Market Y-o-Y Growth, By Approach, 2023-2033 (%)
Figure 8 In-Vivo Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 9 Ex-Vivo Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Gene Therapy Market Y-o-Y Growth, By Vector Type, 2023-2033 (%)
Figure 11 Viral Vectors Vector Type in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 12 Non-Viral Vectors Vector Type in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 13 Global Gene Therapy Market Y-o-Y Growth, By Technique, 2023-2033 (%)
Figure 14 Gene Addition Technique in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 15 Gene Silencing Technique in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 16 Gene Editing Technique in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 17 Global Gene Therapy Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 18 Rare Diseases Application in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 19 Musculoskeletal Conditions Application in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 20 Blood Disorders Application in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 21 Oncology Application in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 22 Ophthalmology Application in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 23 Others Application in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 24 Global Gene Therapy Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 25 North America Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 26 North America Gene Therapy Market Share, By Approach, 2024 & 2033 (%)
Figure 27 North America Gene Therapy Market Share, By Vector Type, 2024 & 2033 (%)
Figure 28 North America Gene Therapy Market Share, By Technique, 2024 & 2033 (%)
Figure 29 North America Gene Therapy Market Share, By Application, 2024 & 2033 (%)
Figure 30 North America Gene Therapy Market Share, By Country, 2024 & 2033 (%)
Figure 31 South America Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 32 South America Gene Therapy Market Share, By Approach, 2024 & 2033 (%)
Figure 33 South America Gene Therapy Market Share, By Vector Type, 2024 & 2033 (%)
Figure 34 South America Gene Therapy Market Share, By Technique, 2024 & 2033 (%)
Figure 35 South America Gene Therapy Market Share, By Application, 2024 & 2033 (%)
Figure 36 South America Gene Therapy Market Share, By Country, 2024 & 2033 (%)
Figure 37 Europe Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 38 Europe Gene Therapy Market Share, By Approach, 2024 & 2033 (%)
Figure 39 Europe Gene Therapy Market Share, By Vector Type, 2024 & 2033 (%)
Figure 40 Europe Gene Therapy Market Share, By Technique, 2024 & 2033 (%)
Figure 41 Europe Gene Therapy Market Share, By Application, 2024 & 2033 (%)
Figure 42 Europe Gene Therapy Market Share, By Country, 2024 & 2033 (%)
Figure 43 Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 44 Asia-Pacific Gene Therapy Market Share, By Approach, 2024 & 2033 (%)
Figure 45 Asia-Pacific Gene Therapy Market Share, By Vector Type, 2024 & 2033 (%)
Figure 46 Asia-Pacific Gene Therapy Market Share, By Technique, 2024 & 2033 (%)
Figure 47 Asia-Pacific Gene Therapy Market Share, By Application, 2024 & 2033 (%)
Figure 48 Asia-Pacific Gene Therapy Market Share, By Country, 2024 & 2033 (%)
Figure 49 Middle East and Africa Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 50 Middle East and Africa Gene Therapy Market Share, By Approach, 2024 & 2033 (%)
Figure 51 Middle East and Africa Gene Therapy Market Share, By Vector Type, 2024 & 2033 (%)
Figure 52 Middle East and Africa Gene Therapy Market Share, By Technique, 2024 & 2033 (%)
Figure 53 Middle East and Africa Gene Therapy Market Share, By Application, 2024 & 2033 (%)
Figure 54 Spark Therapeutics, Inc: Financials
Figure 55 Novartis AG: Financials
Figure 56 bluebird bio, Inc.: Financials
Figure 57 Ferring Pharmaceuticals Inc.: Financials
Figure 58 Vertex Pharmaceuticals Incorporated: Financials
Figure 59 Sarepta Therapeutics, Inc.: Financials
Figure 60 CSL Behring LLC: Financials
Figure 61 Alnylam Pharmaceuticals, Inc.: Financials
Figure 62 Amgen, Inc.: Financials
Figure 63 Orchard Therapeutics group.: Financials
Figure 64 Krystal Biotech, Inc.: Financials
Figure 1 Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Gene Therapy Market Share, By Approach, 2024 & 2033 (%)
Figure 3 Global Gene Therapy Market Share, By Vector Type, 2024 & 2033 (%)
Figure 4 Global Gene Therapy Market Share, By Technique, 2024 & 2033 (%)
Figure 5 Global Gene Therapy Market Share, By Application, 2024 & 2033 (%)
Figure 6 Global Gene Therapy Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Gene Therapy Market Y-o-Y Growth, By Approach, 2023-2033 (%)
Figure 8 In-Vivo Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 9 Ex-Vivo Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Gene Therapy Market Y-o-Y Growth, By Vector Type, 2023-2033 (%)
Figure 11 Viral Vectors Vector Type in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 12 Non-Viral Vectors Vector Type in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 13 Global Gene Therapy Market Y-o-Y Growth, By Technique, 2023-2033 (%)
Figure 14 Gene Addition Technique in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 15 Gene Silencing Technique in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 16 Gene Editing Technique in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 17 Global Gene Therapy Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 18 Rare Diseases Application in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 19 Musculoskeletal Conditions Application in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 20 Blood Disorders Application in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 21 Oncology Application in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 22 Ophthalmology Application in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 23 Others Application in Global Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 24 Global Gene Therapy Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 25 North America Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 26 North America Gene Therapy Market Share, By Approach, 2024 & 2033 (%)
Figure 27 North America Gene Therapy Market Share, By Vector Type, 2024 & 2033 (%)
Figure 28 North America Gene Therapy Market Share, By Technique, 2024 & 2033 (%)
Figure 29 North America Gene Therapy Market Share, By Application, 2024 & 2033 (%)
Figure 30 North America Gene Therapy Market Share, By Country, 2024 & 2033 (%)
Figure 31 South America Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 32 South America Gene Therapy Market Share, By Approach, 2024 & 2033 (%)
Figure 33 South America Gene Therapy Market Share, By Vector Type, 2024 & 2033 (%)
Figure 34 South America Gene Therapy Market Share, By Technique, 2024 & 2033 (%)
Figure 35 South America Gene Therapy Market Share, By Application, 2024 & 2033 (%)
Figure 36 South America Gene Therapy Market Share, By Country, 2024 & 2033 (%)
Figure 37 Europe Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 38 Europe Gene Therapy Market Share, By Approach, 2024 & 2033 (%)
Figure 39 Europe Gene Therapy Market Share, By Vector Type, 2024 & 2033 (%)
Figure 40 Europe Gene Therapy Market Share, By Technique, 2024 & 2033 (%)
Figure 41 Europe Gene Therapy Market Share, By Application, 2024 & 2033 (%)
Figure 42 Europe Gene Therapy Market Share, By Country, 2024 & 2033 (%)
Figure 43 Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 44 Asia-Pacific Gene Therapy Market Share, By Approach, 2024 & 2033 (%)
Figure 45 Asia-Pacific Gene Therapy Market Share, By Vector Type, 2024 & 2033 (%)
Figure 46 Asia-Pacific Gene Therapy Market Share, By Technique, 2024 & 2033 (%)
Figure 47 Asia-Pacific Gene Therapy Market Share, By Application, 2024 & 2033 (%)
Figure 48 Asia-Pacific Gene Therapy Market Share, By Country, 2024 & 2033 (%)
Figure 49 Middle East and Africa Gene Therapy Market Value, 2022-2033 (US$ Billion)
Figure 50 Middle East and Africa Gene Therapy Market Share, By Approach, 2024 & 2033 (%)
Figure 51 Middle East and Africa Gene Therapy Market Share, By Vector Type, 2024 & 2033 (%)
Figure 52 Middle East and Africa Gene Therapy Market Share, By Technique, 2024 & 2033 (%)
Figure 53 Middle East and Africa Gene Therapy Market Share, By Application, 2024 & 2033 (%)
Figure 54 Spark Therapeutics, Inc: Financials
Figure 55 Novartis AG: Financials
Figure 56 bluebird bio, Inc.: Financials
Figure 57 Ferring Pharmaceuticals Inc.: Financials
Figure 58 Vertex Pharmaceuticals Incorporated: Financials
Figure 59 Sarepta Therapeutics, Inc.: Financials
Figure 60 CSL Behring LLC: Financials
Figure 61 Alnylam Pharmaceuticals, Inc.: Financials
Figure 62 Amgen, Inc.: Financials
Figure 63 Orchard Therapeutics group.: Financials
Figure 64 Krystal Biotech, Inc.: Financials
